Proposing a framework to quantify the potential impact of pharmacokinetic drug–drug interactions caused by a new drug candidate by using real world data about the target patient population
Abstract Drug development teams must evaluate the risk/benefit profile of new drug candidates that perpetrate drug–drug interactions (DDIs). Real‐world data (RWD) can inform this decision. The purpose of this study was to develop a predicted impact score for DDIs perpetrated by three hypothetical dr...
Main Authors: | Simon Dagenais, Christine Lee, Carol Cronenberger, Ellen Wang, Vaishali Sahasrabudhe |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2024-03-01
|
Series: | Clinical and Translational Science |
Online Access: | https://doi.org/10.1111/cts.13741 |
Similar Items
-
Pharmacokinetic Drug–Drug Interactions and Herb–Drug Interactions
by: Min-Koo Choi, et al.
Published: (2021-04-01) -
Direct Acting Antiviral Drugs: Pharmacokinetics and Drug-Drug Interactions
by: Marina Barakat, et al.
Published: (2022-12-01) -
Drugs and Drug Candidates: Year in Review
by: Jean Jacques Vanden Eynde
Published: (2024-01-01) -
Pharmacokinetics of tenvermectin in swine, a novel antiparasitic drug candidate—comparison with ivermectin
by: Guiyu Li, et al.
Published: (2023-05-01) -
Enantiospecific pharmacokinetics and drug-drug interactions of primaquine and blood-stage antimalarial drugs
by: Chairat, K, et al.
Published: (2018)